Hemorrhagic Fever With Renal Syndrome
Conditions
Brief summary
Thrombocytopenia is an important pathological feature of HFRS（Hemorrhagic Fever With Renal Syndrome, HFRS）. However, the cause of thrombocytopenia in HFRS is not yet fully understood. Neutrophils, as the largest number of white blood cells in the human body, can widely participate in the immune process of viral infections. Previous studies have found that the neutrophils of patients with acute myocardial infarction can interact with activated platelets and further mediate platelet phagocytosis.Therefore, this study aims to systematically elucidate the immunological process of neutrophil mediated thrombocytopenia in patients with HFRS by exploring the correlation between platelet activation, neutrophil activation and neutrophil proportion of adherent / phagocytic platelets peripheral blood of HFRS patients, and to analyze its relationship with the course of HFRS disease, which lays a theoretical foundation for further understanding the pathogenesis of HFRS and provides a basis for clinical use.
Interventions
OTHERclinical classification of HFRS
Based upon clinical classification of HFRS , the patients were classified into four types
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age ≥18 years; * Clinical diagnosis meets the diagnostic criteria of the national HFRS prevention and treatment plan (Hantavirus-specific IgM antibody is positive). The classification and staging standards of HFRS patients are based on the Expert Consensus of Shaanxi Province on Diagnosis and Treatment of Hemorrhagic Fever with Renal Syndrome.
Exclusion criteria
* Age \<18 years; * Have a history of kidney disease; * Have a history of liver disease; * Have a history of malignant tumor; * Receive dialysis treatment before admission; * Combined with hypertension, coronary heart disease and diabetes history; * Combined with HIV infection and patients with autoimmune diseases and pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the platelet activation ratio, % | through study completion, an average of 2 year | flow cytometry |
| Changes in neutrophils MPO content, MFI | through study completion, an average of 2 year | enzyme-linked immunosorbent assay |
| Changes in the neutrophils with adherent platelets, % | through study completion, an average of 2 year | flow cytometry |
| Changes in the neutrophils with internalized platelets, % | through study completion, an average of 2 year | flow cytometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Neutrophils Mac-1 expression, MFI | through study completion, an average of 2 year | flow cytometry |
| Changes in the platelets with phosphatidylserine exposure,% | through study completion, an average of 2 year | flow cytometry |
Countries
China
Contacts
Primary Contactxiaojiao Li
Backup Contactlin Su
Outcome results
None listed